S1202
Clinical - Urology
ESTRO 2026
1 Radiation Oncology department, Groupe Orion, Clinique Pasteur, Toulouse, France. 2 Urology Andrology department, CHU Caremeau, Nîmes, France. 3 Medical department, Ipsen, Paris, France. 4 Biometry department, Ipsen, Paris, France. 5 Urology department, Saint-Louis Hospital, Université Paris Cité, Paris, France Purpose/Objective: Impact of androgen deprivation therapy (ADT), like triptorelin, on health-related quality of life (HRQoL) is well-known in literature, but data in real life are scarce. Our purpose was to study it in a large population of patients after a 6-month treatment. Material/Methods: Individual data from 3 observational studies conducted prospectively in France (FOCUS 2008-10, EQUINOXE 2015-17, TALISMAN 2020-22) were pooled, with patients having histologically confirmed PCa, and data on HRQoL evaluated with QLQ-PR25 questionnaire at baseline and after a 6-month treatment with triptorelin. Data were anonymized to allow patients privacy. Primary objective was to analyze the impact of triptorelin on HRQoL, evaluated with QLQ-PR25, hormonal treatment-related symptoms (HTRS) and sexual activity (SA) subscales, after a 6-month follow-up (6mFU). Subgroup analyses included analysis by age groups. Results: The final analysis included 1723 patients. Descriptive statistics for main baseline parameters, in the study population and by age groups, are presented in Table 1. Patients under 75 years old had more surgery as previous treatment and more radiotherapy as concomitant treatment to triptorelin, compared with patients aged 75 years and older. Patients aged 80 years and older had the highest rate of previous hormonal treatment. Baseline and 6mFU scores of QLQ-PR25 domains, and their changes from baseline to 6mFU, are presented in Table 2. Mean (sd) scores changes were, respectively, 8.37 (15.97) for HTRS and - 8.22 (22.26) for SA subscales, meaning there was a small (< 10 points) deterioration of both subscales. Results of HTRS domain scores by age groups showed slight smaller change in patients aged 80 years and older. Results of SA domain scores by age groups showed a diminution of baseline scores with increasing age and highest SA scores changes in younger patients. From multivariate analyses, age group ( ≥ 80y vs [70-75y[) was linked with improvement of HTRS (lower scores) and deterioration of SA (lower scores). Data collected across these studies showed no new or unexpected safety concerns.
Conclusion: Radical RT for MRN involvement is feasible with low GI toxicity rates. MRN–rectum proximity was the key determinant of G2GI toxicity, seen only when MRNs were ≤ 1mm from rectal wall and received a boost. When MRNs are further away, RT with a boost appears safe. Longer follow-up and prospective validation in larger cohorts are warranted. References: 1. Pedersen CK, Babu AS. Understanding the Lymphatics: An Updated Review of the N Category of the AJCC 8th Edition for Urogenital Cancers. Am J Roentgenol 2021; 217(2): 368–377. Keywords: Prostate, Mesorectal, Toxicity
Poster Discussion 1917
Changes in health-related quality of life in patients with prostate cancer initiating triptorelin: focus on age groups Igor Latorzeff 1 , Stéphane Droupy 2 , Nathalie Pello- Leprince-Ringuet 3 , Marie-Cécile Fournier 4 , Pierre Mongiat-Artus 5
Made with FlippingBook - Share PDF online